Drugs / LB-LR1109
last change Jun 2024 re-read 2 minutes ago

LB-LR1109

Developed for
head and neck squamous cell carcinoma · melanoma · non-small cell lung carcinoma · renal cell carcinoma · urothelial carcinoma
Investigated by
LG Chem

Trials 1 · a red edge is where a trial was stopped

202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT06332755 Jun 2024 → Nov 2027 expected head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, renal cell carcinoma +1 LG Chem Recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LB-LR1109 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06332755